Table 1

Adrenocortical carcinoma: patients’ and tumor characteristics

NAge
(years)
Sex
(male/female (n))
Size of tumor (cm)Ki67 index (%)Glucocorticoids
+/−other steroids
Only sex hormonesOther steroid patternNo steroid excessHormone profile n/a
All ACC samples 14647 (18–77)45/10110.0
(0.5–30.0)
10 (0–80)63 (36/27)1273133
Primary tumors 10747 (18–77)32/7511.8
(3.3–30.0)
10 (0–80)44 (29/15)942327
 ENSAT I/II*4746 (18–77)13/3412.0
(3.3–28.0)
10 (0–50)17 (10/7)63147
 ENSAT III*3847 (18–75)13/2510.3
(5.0–30.0)
20 (1–80)16 (10/6)31711
 ENSAT IV*2047.5 (24–72)6/1413.0
(7.0–25.0)
10 (1–30)11 (9/2)0036
Local recurrences1644 (20–70)6/104.5
(1.5–9.4)
12.5 (5–20)6 (2/4)2233
Distant metastases2341 (19–72)7/161.7
(0.5–4.0)
17.5 (5–40)13 (8/5)1144
  • Data represent median values with ranges or total numbers.

  • *Tumor stage at the time of diagnosis according to the European Network for the Study of Adrenal Tumors (ENSAT) classification.40

  • †In patients who experienced local recurrences or distant metastases during mitotane treatment, endocrine activity was classified according the information available at primary diagnosis.

  • ACC, adrenocortical carcinoma.